---
title: "NovaBridge Biosciences (NBP.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/NBP.US.md"
symbol: "NBP.US"
name: "NovaBridge Biosciences"
industry: "Biotechnology"
---

# NovaBridge Biosciences (NBP.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.novabridge.com](https://www.novabridge.com) |

## Company Profile

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 ...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -14.41 | 478/603 | - | - | - |
| PB | 1.47 | 135/603 | 2.44 | 1.95 | 1.64 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T05:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.24 |
| Highest Target | 10.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/NBP.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/NBP.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/NBP.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.